cjc 1295 no dac with ipamorelin CJC-1295 (No DAC) 5mg, 5mg (Blend) CJC-1295 no DAC + Ipamorelin

Cancer Sci 103:760766 Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M (2020) Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer

reported a 40% decrease in IGF-1 protein levels during the early stages of tendon healing compared to intact tendons, with levels peaking at 4 weeks and remaining elevated through 8 weeks post-injury (Tang et al., 2019)

CJC1295 increases GH release through GHRH pathways, while Ipamorelin stimulates GH through GHRP (ghrelin) receptors

Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1